Tradestie Institutional Equity Comparison Engine
PCVX vs MLTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
PCVX Overall Edge
PCVX Captures Institutional Edge (2โ1 Pillars ยท 5โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Vaxcyte, Inc. Common Stock (PCVX) driven by superior Growth & Margin, Momentum & Technical while MLTX counters with relative strength in Options & Structure. Fundamentally, PCVX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MLTX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, PCVX sits in CONSOLIDATION (10th %ile IV; Dealer Gamma Walls on Pro) against MLTX sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
PCVX N/M vs MLTX N/M Fwd P/E
Growth & Margin Winner
PCVX
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner
PCVX
1Y +36.2% vs -5.7% ยท 52W Pos 41% vs 17%
Options & Structure Winner
MLTX
CONSOLIDATION (10th %ile IV) vs BREAKDOWN (7th %ile IV)
PCVX
NASDAQ
Vaxcyte, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$62.04
-2.1% 1D
Market Cap
$10.2B
1M Return
-2.48%
1Y Return
+36.2%
Forward P/E
N/M
Unified AI Score
47.3 / 100
HOLD
Tech 42.0
Fund 50.0
Flow 65.0
Mom 50.0
MLTX
NASDAQ
MoonLake Immunotherapeutics Class A Ordinary Shares
Pharmaceutical Preparations
$11.85
-5.2% 1D
Market Cap
$1.1B
1M Return
+24.08%
1Y Return
-5.65%
Forward P/E
N/M
Unified AI Score
38.3 / 100
SELL
Tech 32.0
Fund 44.0
Flow 75.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
PCVX +36.2%
MLTX -5.65%
Spread: +41.85 pp (PCVX Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
PCVX TTM Op. Margin: 0.0%
MLTX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PCVX vs MLTX. Trailing 12-month operating profitability (PCVX 0.0% vs MLTX 0.0%) and valuation multiples (PCVX N/M vs MLTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | PCVX | MLTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $10.2B | $1.1B | Larger Scale | PCVX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -42.7% | -81.5% | Higher ROE | PCVX |
| 52-Week Range Position Momentum | 41% ($42โ$91) | 17% ($9โ$23) | Stronger Trend | PCVX |
| Beta / 30D Volatility Risk Regime | 1.29ฮฒ ยท 57% Vol | 1.61ฮฒ ยท 90% Vol | Lower Realized Risk | PCVX |
| Unified Institutional Score Composite Signal | 47.3 / 100 (HOLD) | 38.3 / 100 (SELL) | Higher Composite | PCVX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full PCVX vs MLTX Buy Guide
PCVX
CONSOLIDATION
62d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
10th %ile
IV Regime
Compressed (<25th %ile)
MLTX
BREAKDOWN
103d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
7th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither PCVX nor MLTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.